Legal entity
Every one of those 1 sits in a single category, regulation. Brookings Institution is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 8, the average consequence score sits above the same-window beat average of 6.5.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. Brookings Institution is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 8, the average consequence score sits above the same-window beat average of 6.5. Source depth averages 3 original sources per story, versus 2.3 across the same-window beat baseline. We currently track 1 Legal story that mention Marta Wosinska, all published on March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 45 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Marta Wosinska. Shared-story counts are live from our verified record — not editorial picks.
The House Select Committee on China has raised alarms over the United States' increasing reliance on Chinese-made active pharmaceutical ingredients and biotech innovation. Lawmakers argue that Beijing is applying a proven industrial playbook to dominate the global medicine supply chain, posing significant national security and regulatory challenges.
Source: Lucy Quaggin (cn) · Lucy Quaggin (hk)
Marta Wosinska is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
